Drug Profile
Research programme: atherosclerosis vaccine - AFFiRiS
Alternative Names: ATH-05Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Peptide vaccines
- Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Atherosclerosis in Austria (Parenteral) (AFFiRiS pipeline, April 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Atherosclerosis in Austria (Parenteral)
- 20 Jun 2014 Preclinical trials in Atherosclerosis in Austria (Parenteral)